Drugs / Dolutegravir/Lamivudine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06497465 | Sep 2025 → Jan 2028 expected | HIV infectious disease, tuberculosis | Johns Hopkins University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dolutegravir/Lamivudine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06497465 ↗ |
| Known as | DOVATO | “Participants will receive Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]” NCT06497465 ↗ |
| Route | Oral | “Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]” NCT06497465 ↗ |